| EPD339 | Motivations for starting and stopping PrEP: experiences of AGYW in the HPTN 082 study | E-poster | Conceptualizing social and structural factors and their impacts |
| EPE148 | Moving from biomedical HIV prevention to 'V ineka that, that, that!': early insights from implementing 'V' in Zimbabwe | E-poster | Scaling up services for adolescents and youth |
| EPE079 | Moving from rhetoric to reality: lessons learned from integrating oral PrEP and family planning services in public health facilities in Nairobi, Kenya | E-poster | Scaling up access to models of integrated services (HIV, hepatitis, STI and other services, such as harm reduction, SRHR, gender affirming care, TB, NCDs and mental health) |
| OAE0204 | MPOWER yourself: an online HIV self-test service to increase testing among gbMSM during COVID-19 restrictions | Oral abstract session with live Q&A | Optimizing HIV services (prevention, testing and/or treatment) in the COVID-19 era |
| EPE402 | MSM / TG communities impacted by covid 19 lockdown resulting in increased hiv prevalence and low testing- anexploratory study from india | E-poster | Impact of COVID-19 on HIV testing services |
| EPB134 | Multi-medicine use and potential drug'drug interactions among people living with HIV on antiretroviral therapy in Australia | E-poster | Drug-drug interaction (DDI) |
| EPA045 | Multi-modal statistical analysis strategies identify biomarkers of cell-associated Gag RNA expression levels during ART | E-poster | Host cellular factors and viral mechanisms of HIV/SIV persistence and latency |
| EPE174 | Multi-month dispensing and use of dolutegravir associated with better viral suppression among children in Nigeria | E-poster | Differentiated service delivery for HIV testing, prevention and treatment |
| EPC473 | Multiple strategies are needed for enrolling individuals in randomized COVID-19 trials. Lessons learned from a home base postexposure trial in Argentina | E-poster | COVID-19 prevention |
| EPA037 | MVA/Protein HIV-1 vaccine protects against heterologous SHIV infection by modulating IgG glycosylation and T helper response in macaques | E-poster | Novel vectors, adjuvants and strategies |